Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Original Submission
19 Jun 2017 Submitted Original manuscript
12 Jul 2017 Reviewed Reviewer Report - Frank G. A. Jansman
25 Jul 2017 Reviewed Reviewer Report - Jeonghoon Ahn
13 Aug 2017 Reviewed Reviewer Report - Rei Goto
30 Aug 2017 Author responded Author comments - Takeru Shiroiwa
Resubmission - Version 2
30 Aug 2017 Submitted Manuscript version 2
1 Sep 2017 Reviewed Reviewer Report - Frank G. A. Jansman
1 Sep 2017 Reviewed Reviewer Report - Jeonghoon Ahn
13 Sep 2017 Reviewed Reviewer Report - Rei Goto
28 Sep 2017 Author responded Author comments - Takeru Shiroiwa
Resubmission - Version 3
28 Sep 2017 Submitted Manuscript version 3
2 Oct 2017 Reviewed Reviewer Report - Frank G. A. Jansman
12 Oct 2017 Author responded Author comments - Takeru Shiroiwa
Resubmission - Version 4
12 Oct 2017 Submitted Manuscript version 4
4 Nov 2017 Author responded Author comments - Takeru Shiroiwa
Resubmission - Version 5
4 Nov 2017 Submitted Manuscript version 5
9 Nov 2017 Author responded Author comments - Takeru Shiroiwa
Resubmission - Version 6
9 Nov 2017 Submitted Manuscript version 6
Publishing
13 Nov 2017 Editorially accepted
17 Nov 2017 Article published 10.1186/s12885-017-3774-7

You can find further information about peer review here.

Back to article page